JP2015078199A5 - - Google Patents

Download PDF

Info

Publication number
JP2015078199A5
JP2015078199A5 JP2014231450A JP2014231450A JP2015078199A5 JP 2015078199 A5 JP2015078199 A5 JP 2015078199A5 JP 2014231450 A JP2014231450 A JP 2014231450A JP 2014231450 A JP2014231450 A JP 2014231450A JP 2015078199 A5 JP2015078199 A5 JP 2015078199A5
Authority
JP
Japan
Prior art keywords
cancer
diseases
mek
heptane
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014231450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015078199A (ja
JP6309880B2 (ja
Filing date
Publication date
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Application filed filed Critical
Publication of JP2015078199A publication Critical patent/JP2015078199A/ja
Publication of JP2015078199A5 publication Critical patent/JP2015078199A5/ja
Application granted granted Critical
Publication of JP6309880B2 publication Critical patent/JP6309880B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2014231450A 2007-07-30 2014-11-14 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法 Expired - Fee Related JP6309880B2 (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US11/830,733 2007-07-30
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446408P 2008-03-06 2008-03-06
US3446608P 2008-03-06 2008-03-06
US61/034,466 2008-03-06
US61/034,464 2008-03-06
US4488608P 2008-04-14 2008-04-14
US61/044,886 2008-04-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010520118A Division JP2010535232A (ja) 2007-07-30 2008-07-28 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017018477A Division JP2017125021A (ja) 2007-07-30 2017-02-03 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法

Publications (3)

Publication Number Publication Date
JP2015078199A JP2015078199A (ja) 2015-04-23
JP2015078199A5 true JP2015078199A5 (enExample) 2016-05-26
JP6309880B2 JP6309880B2 (ja) 2018-04-11

Family

ID=40304796

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010520118A Pending JP2010535232A (ja) 2007-07-30 2008-07-28 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法
JP2014231450A Expired - Fee Related JP6309880B2 (ja) 2007-07-30 2014-11-14 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法
JP2017018477A Pending JP2017125021A (ja) 2007-07-30 2017-02-03 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010520118A Pending JP2010535232A (ja) 2007-07-30 2008-07-28 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017018477A Pending JP2017125021A (ja) 2007-07-30 2017-02-03 Ｍｅｋの阻害剤としての多形体を含む、ｎ−（アリールアミノ）スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法

Country Status (22)

Country Link
EP (1) EP2184984A4 (enExample)
JP (3) JP2010535232A (enExample)
KR (3) KR20150091434A (enExample)
CN (2) CN103479604B (enExample)
AP (1) AP2817A (enExample)
AU (2) AU2008282338B2 (enExample)
BR (1) BRPI0815659A2 (enExample)
CA (1) CA2693390C (enExample)
CO (1) CO6470808A2 (enExample)
CR (1) CR11244A (enExample)
DO (1) DOP2010000045A (enExample)
EA (2) EA032294B1 (enExample)
EC (1) ECSP109910A (enExample)
HN (1) HN2010000203A (enExample)
IL (1) IL203296A (enExample)
MA (1) MA31881B1 (enExample)
MX (1) MX2010001244A (enExample)
NZ (1) NZ582929A (enExample)
PH (1) PH12015501914A1 (enExample)
SV (1) SV2010003469A (enExample)
TN (1) TN2010000049A1 (enExample)
WO (1) WO2009018233A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2291350A4 (en) * 2008-04-14 2012-09-19 Ardea Biosciences Inc COMPOSITIONS AND METHODS FOR THEIR MANUFACTURE AND USE
BR122021020474B1 (pt) * 2008-09-09 2022-06-07 F. Hoffmann-La Roche Ag Polimorfos de acil sulfonamidas, seu uso, seu processo de preparação e composição farmacêutica que os compreende
BRPI0919473A2 (pt) 2008-09-26 2017-08-29 Oncomed Pharm Inc Agentes de ligação frizzled e usos dos mesmos
PE20120105A1 (es) 2009-03-11 2012-02-22 Ardea Biosciences Inc Combinaciones farmaceuticas que comprenden refametinib
UY32486A (es) * 2009-03-11 2010-10-29 Ardea Biosciences Inc Tratamiento del cáncer de páncreas
CN102666512B (zh) 2009-10-13 2014-11-26 奥斯特姆医疗公司 对疾病治疗有用的mek抑制剂
WO2011047788A1 (en) * 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
CN102649773A (zh) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途
NZ618062A (en) * 2011-04-28 2016-04-29 Sloan Kettering Inst Cancer Hsp90 combination therapy
WO2012163799A1 (en) * 2011-05-27 2012-12-06 Bayer Intellectual Property Gmbh Chiral synthesis of n-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamides
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
US20150267258A1 (en) * 2012-05-31 2015-09-24 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
TWI662963B (zh) 2012-06-04 2019-06-21 美商製藥有限責任公司 布魯頓氏酪胺酸激酶抑制劑之結晶形式
SI2909182T1 (sl) * 2012-10-19 2020-03-31 Array Biopharma Inc. Priprava inhibitorja MEK in formulacije, ki obsegajo inhibitor MEK
CA2890238A1 (en) 2012-11-02 2014-05-08 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
EP2848246A1 (en) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
KR102541110B1 (ko) 2014-08-25 2023-06-08 에이뮨 테라퓨틱스, 인코퍼레이티드 난 단백질 제형 및 이의 제조 방법
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
WO2018232235A1 (en) 2017-06-16 2018-12-20 Beta Pharma, Inc. Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021067772A1 (en) * 2019-10-04 2021-04-08 Sumitomo Dainippon Pharma Oncology, Inc. Axl inhibitor formulations
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
CN118834328B (zh) * 2024-07-02 2025-09-16 江苏海洋大学 金属蛋白酶9抗原决定基印迹纳米颗粒的制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (ja) * 1992-07-31 1997-01-29 塩野義製薬株式会社 トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
EP0656887B1 (en) * 1992-08-25 1998-10-28 G.D. Searle & Co. Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
IL144215A0 (en) * 1999-01-13 2002-05-23 Warner Lambert Co 1-heterocycle substituted diarylamines
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
JP2005508322A (ja) * 2001-09-24 2005-03-31 ジェシー エル エス オウ 併用療法に用いられるスラミンの化学増感用量を決定するための方法及び成分
MXPA05000555A (es) * 2002-07-17 2005-04-28 Titan Pharmaceuticals Inc Combinacion de farmacos quimioterapeuticos para incrementar la actividad antitumoral.
WO2004012744A1 (de) * 2002-07-30 2004-02-12 Zentaris Gmbh Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten
WO2006110811A1 (en) * 2005-04-12 2006-10-19 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
PE20061317A1 (es) * 2005-04-22 2006-12-29 Kissei Pharmaceutical Cristal polimorfico de hidrocloruro del acido 4'-{2-[(1s,2r)-2-hidroxi-2-(4-hidroxifenil)-1-metiletilamino]etoxi}-3-isopropil-3'-5'-dimetilbifenilcarboxilico
EP1912636B1 (en) * 2005-07-21 2014-06-25 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JP2007099763A (ja) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd ピペラシリンナトリウム・１水和物の新規な結晶及びその製造方法
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Similar Documents

Publication Publication Date Title
JP2015078199A5 (enExample)
JP2018520205A5 (enExample)
CN115244058A (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
HRP20192209T1 (hr) Derivati benzofurana, postupci njihove pripreme i njihova uporaba u medicini
JP2017507175A5 (enExample)
JP2019518766A5 (enExample)
JP2013525363A5 (enExample)
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
HRP20180499T1 (hr) Spojevi i postupci za modulaciju kinaze, te odgovarajuće indikacije
RU2019101220A (ru) Кристаллические формы соединения триазолопиримидина
JP2013535491A5 (enExample)
JP2013525458A5 (enExample)
JP2016501221A5 (enExample)
HRP20140486T1 (hr) Postupci sinteze spojeva spirooksindola
ME02452B (me) Sredstva za induciranje apoptoze namijenjena liječenju raka i imunih i autoimunih bolesti
RU2017136715A (ru) Производное имидазоизоиндола, способ его получения и медицинское применение
JP2014534269A5 (enExample)
JP2017511321A5 (enExample)
JP2019522055A5 (enExample)
JP2016531108A5 (enExample)
JP2022071077A5 (enExample)
JP2016528273A5 (enExample)
RU2016133731A (ru) Функционализованные соединения бензопирана и их применение
JP2013523680A5 (enExample)
JP2016504325A5 (enExample)